We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

77 hedge funds and large institutions have $80.2M invested in Jounce Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 80 → 77 (-3)

25% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 12

34% less capital invested

Capital invested by funds: $122M → $80.2M (-$41.4M)

Holders
77
Holders Change
-3
Holders Change %
-3.75%
% of All Funds
1.69%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
29
Reduced
22
Closed
12
Calls
$57K
Puts
–
Net Calls
+$57K
Net Calls Change
-$46K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$635K
2
EIM
Essex Investment Management
Massachusetts
+$433K
3
BlackRock
BlackRock
New York
+$401K
4
JP Morgan Chase
JP Morgan Chase
New York
+$261K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$258K

Top Sellers

Rank Fund Capital Flow
1
AQR Capital Management
AQR Capital Management
Connecticut
-$1.43M
2
RG
Redmile Group
California
-$1.26M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.03M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$726K
5
Prudential Financial
Prudential Financial
New Jersey
-$472K
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
76
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Royal Bank of Canada
77
Royal Bank of Canada
Ontario, Canada
$1K – – –
AQR Capital Management
78
AQR Capital Management
Connecticut
– -$1.43M -288,422 Closed
RG
79
Redmile Group
California
– -$1.26M -254,590 Closed
Assenagon Asset Management
80
Assenagon Asset Management
Luxembourg
– -$1.03M -207,200 Closed
DCM
81
Dupont Capital Management
Delaware
– -$321K -64,826 Closed
USAA
82
United Services Automobile Association
Texas
– -$152K -30,675 Closed
State of Wisconsin Investment Board
83
State of Wisconsin Investment Board
Wisconsin
– -$107K -21,600 Closed
Man Group
84
Man Group
United Kingdom
– -$80K -16,090 Closed
SIM
85
Spark Investment Management
New York
– -$60K -12,200 Closed
ARTA
86
A.R.T. Advisors
New York
– -$59K -11,900 Closed
Federated Hermes
87
Federated Hermes
Pennsylvania
– -$2K -362 Closed
Simplex Trading
88
Simplex Trading
Illinois
– -$937 -234 Closed
PCP
89
Proficio Capital Partners
Massachusetts
– -$1K -105 Closed
1 2 3
4

JNCE Hedge Fund Activity: Q3 2019 in Review

77 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2019, worth a combined $80.2M — down 34% from $122M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of JNCE and 9 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 29 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $635K. The largest seller was AQR Capital Management, exiting entirely with an estimated $1.43M sold.

  • 77 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2019, down from 80 in Q2 2019.
  • Funds reported $80.2M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2019, down 34% quarter-over-quarter.
  • 9 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2019 and 12 closed out, a net change of -3 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2019 was Millennium Management, an estimated $635K added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2019 was AQR Capital Management, an estimated $1.43M sold.

Based on aggregated 13F filings for Q3 2019.